Appendix Table 3.

Trends in Medication Use Over Time for Children Hospitalized with COVID-19 Stratified by Disease Severity, Interrupted Time Series Parameter Estimates on Logit Scale (Corresponding to Figure 2)

		Mild-Moderate		Severe (non-critical)		Critical
		Estimate (95% CI)	p-value	Estimate (95% CI)	p-value	Estimate (95% CI)	p-value
Enoxaparin
	Pre-guideline slope	0.02 (−0.04, 0.08)	0.448	−0.08 (−0.18, 0.02)	0.124	−0.03 (−0.12, 0.06)	0.505
	Level change immediately after guideline	−0.2 (−0.44, 0.04)	0.108	−0.28 (−0.71, 0.15)	0.208	0.17 (−0.19, 0.54)	0.355
	Change in slope	−0.02 (−0.08, 0.04)	0.577	0.13 (0.02, 0.23)	0.017	0.04 (−0.06, 0.13)	0.440
	Post-guideline slope	0.01 (−0.01, 0.02)	0.466	0.05 (0.02, 0.08)	< 0.001	0.01 (−0.02, 0.03)	0.610
Remdesivir
	Pre-guideline slope	0.39 (0.23, 0.54)	< 0.001	0.22 (0.08, 0.36)	0.002	0.33 (0.2, 0.46)	< 0.001
	Level change immediately after guideline	−0.65 (−1.01, −0.3)	0.001	−0.47 (−0.95, 0)	0.058	0.45 (0.02, 0.87)	0.046
	Change in slope	−0.33 (−0.48, −0.17)	< 0.001	−0.13 (−0.27, 0.01)	0.063	−0.21 (−0.34, −0.08)	0.002
	Post-guideline slope	0.06 (0.04, 0.07)	< 0.001	0.09 (0.06, 0.11)	< 0.001	0.12 (0.1, 0.15)	< 0.001
Steroids
	Pre-guideline slope	0.15 (0.1, 0.2)	< 0.001	0.13 (0.03, 0.24)	0.009	0.23 (0.12, 0.33)	< 0.001
	Level change immediately after guideline	−0.09 (−0.28, 0.09)	0.340	−0.18 (−0.61, 0.26)	0.431	0.41 (−0.05, 0.88)	0.086
	Change in slope	−0.12 (−0.17, −0.06)	< 0.001	−0.05 (−0.15, 0.06)	0.394	−0.21 (−0.31, −0.1)	< 0.001
	Post-guideline slope	0.04 (0.02, 0.05)	< 0.001	0.09 (0.06, 0.12)	< 0.001	0.02 (−0.01, 0.05)	0.242

Abbreviations: CI: Confidence Interval

Event point is IDSA Guideline Version 3.5.1 online publication December 2, 2020. Slope is trend in medication use. Level change immediately after guideline represents change in series at event point (end of pre-guideline versus start of post-guideline period); change in slope is difference in slopes between pre- and post-guideline periods.